StockData

Endonovo Therapeutics, Inc. (ENDV) stock

ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $135.08KP/E –Yield –

Endonovo Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Endonovo Therapeutics's gross margin for the twelve months ending Sep 30, 2023 was 96.2%. For fiscal 2022 it was 92.6%, against 79.5% the year before. The highest annual figure on record is 92.6% in fiscal 2022.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2022Dec 31, 202292.6%+13.1
FY2021Dec 31, 202179.5%+18.9
FY2020Dec 31, 202060.6%−9.3
FY2019Dec 31, 201969.9%−14.6
FY2018Dec 31, 201884.5%+35.2
FY2015Dec 31, 201549.3%+13.3
FY2014Dec 31, 201436.0%−2.9
FY2013Dec 31, 201338.9%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2023Sep 30, 202345.6%−17.7
Q2 FY2023Jun 30, 2023100.0%+58.9
Q1 FY2023Mar 31, 202395.4%+26.7
Q4 FY2022Dec 31, 202296.0%+2800.1
Q3 FY2022Sep 30, 202263.3%+3.1
Q2 FY2022Jun 30, 202241.1%−57.3
Q1 FY2022Mar 31, 202268.7%−24.0
Q4 FY2021Dec 31, 2021-2704.1%−2395.0
Q3 FY2021Sep 30, 202160.2%−37.9
Q2 FY2021Jun 30, 202198.3%+23.7
Q1 FY2021Mar 31, 202192.7%+1.7
Q4 FY2020Dec 31, 2020-309.1%−377.3
Q3 FY2020Sep 30, 202098.1%+14.6
Q2 FY2020Jun 30, 202074.7%+21.8
Q1 FY2020Mar 31, 202091.0%+8.2
Q4 FY2019Dec 31, 201968.2%−12.6
Q3 FY2019Sep 30, 201983.5%+3.7
Q2 FY2019Jun 30, 201952.9%−42.9
Q1 FY2019Mar 31, 201982.8%−17.2
Q4 FY2018Dec 31, 201880.9%+10.9
Q3 FY2018Sep 30, 201879.8%+56.4
Q2 FY2018Jun 30, 201895.7%+31.7
Q1 FY2018Mar 31, 2018100.0%+47.6
Q1 FY2015Mar 31, 201570.0%–
Q3 FY2014Sep 30, 201423.3%–
Q2 FY2014Jun 30, 201464.0%–
Q1 FY2014Mar 31, 201452.4%–

More Endonovo Therapeutics figures

See a number that looks wrong?